Orum Therapeutics, Inc. (KOSDAQ:475830)
South Korea · Delayed Price · Currency is KRW 59,200
-5,800 (-8.92%)
Sep 1, 2026, 3:30 PM KST
Orum Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| 40.55 | 23.56 | 20,906 | 135,418 | 75.92 | |
Revenue Growth | -99.81% | -99.89% | -84.56% | 178270.49% | - |
Cost of Revenue | 0.32 | 0.26 | 1.99 | - | 0.83 |
Gross Profit | 40.23 | 23.31 | 20,904 | 135,418 | 75.09 |
Selling, General & Admin | 13,555 | 12,563 | 9,158 | 19,054 | 9,083 |
Research & Development | 48,433 | 35,653 | 17,043 | 18,706 | 33,168 |
Other Operating Expenses | 389.18 | 269.7 | 170.3 | 280.11 | 182.18 |
Operating Expenses | 65,663 | 51,782 | 29,239 | 39,811 | 43,723 |
Operating Income | -65,622 | -51,759 | -8,335 | 95,607 | -43,648 |
Interest Expense | -1,890 | -1,882 | -1,794 | -824.35 | -75.37 |
Interest & Investment Income | 2,314 | 1,130 | 3,179 | 560.83 | 671 |
Currency Exchange Gain (Loss) | -1,860 | -236.1 | -4,609 | -5,642 | -799.86 |
Other Non Operating Income (Expenses) | 86,307 | 5,693 | 5,445 | -21,199 | -19,197 |
EBT Excluding Unusual Items | 19,249 | -47,054 | -6,114 | 68,502 | -63,050 |
Gain (Loss) on Sale of Investments | -2,860 | 2,906 | 799.27 | -809.55 | -52.63 |
Gain (Loss) on Sale of Assets | -61.17 | -4.13 | - | 205.25 | 8.91 |
Pretax Income | 16,328 | -44,152 | -5,315 | 67,898 | -63,093 |
Income Tax Expense | -2,183 | -2,183 | 424.98 | -319.02 | 225.34 |
Net Income | 18,511 | -41,969 | -5,740 | 68,217 | -63,319 |
Net Income to Common | 18,511 | -41,969 | -5,740 | 68,217 | -63,319 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 21 | 21 | 14 | 5 | 5 |
Shares Outstanding (Diluted) | 21 | 21 | 14 | 15 | 5 |
Shares Change | 9.54% | 53.73% | -10.08% | 227.30% | - |
EPS (Basic) | 869.48 | -2016.61 | -424.00 | 14829.83 | -13764.93 |
EPS (Diluted) | 869.48 | -2016.61 | -424.00 | 5646.14 | -13764.93 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | -52,740 | -36,685 | -12,545 | 93,117 | -41,888 |
Free Cash Flow Per Share | -2477.25 | -1762.70 | -926.66 | 6184.75 | -9106.02 |
Gross Margin | 99.21% | 98.91% | 99.99% | 100.00% | 98.91% |
Operating Margin | -161817.86% | -219651.47% | -39.87% | 70.60% | -57492.65% |
Profit Margin | 45646.42% | -178105.43% | -27.46% | 50.38% | -83402.60% |
Free Cash Flow Margin | -130052.37% | -155680.70% | -60.01% | 68.76% | -55173.99% |
EBITDA | -62,337 | -48,462 | -5,467 | 97,377 | -42,358 |
EBITDA Margin | - | - | -26.15% | 71.91% | - |
D&A For EBITDA | 3,286 | 3,297 | 2,868 | 1,771 | 1,290 |
EBIT | -65,622 | -51,759 | -8,335 | 95,607 | -43,648 |
EBIT Margin | - | - | -39.87% | 70.60% | - |
Advertising Expenses | - | 28.26 | 4.37 | 3.95 | 10.28 |